Cogent Biosciences (COGT) closed at $31.65 on November 6, 2026, up 7.0% from the previous close, on volume of 1,312,607 shares (30-day average 2,065,186).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 6, 2026 | Call Spread | 15-Jan-2750 : 60 C | 4,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Stifel Nicolaus Keeps Their Buy Rating on Cogent Biosciences (COGT)
TipRanks (Fri, 6-Nov 9:36 AM ET)
Cogent Biosciences reports Q3 results
Seeking Alpha News (Thu, 5-Nov 5:54 PM ET)
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results
Globe Newswire (Thu, 5-Nov 4:01 PM ET)
Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference
Globe Newswire (Tue, 27-Oct 4:01 PM ET)
Globe Newswire (Tue, 15-Sep 8:00 AM ET)
Market Chameleon (Mon, 10-Aug 4:59 AM ET)
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
Globe Newswire (Mon, 10-Aug 8:00 AM ET)
Market Chameleon (Mon, 16-Mar 4:37 AM ET)
Market Chameleon (Mon, 12-Jan 4:16 AM ET)
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Cogent Biosciences trades on the NASDAQ stock market under the symbol COGT.
As of November 6, 2026, COGT stock price climbed to $31.65 with 1,312,607 million shares trading.
COGT has a beta of 0.60, meaning it tends to be less sensitive to market movements. COGT has a correlation of 0.01 to the broad based SPY ETF.
COGT has a market cap of $5.49 billion. This is considered a Mid Cap stock.
Last quarter Cogent Biosciences reported $0 in Revenue and -$.59 earnings per share. This fell short of revenue expectation by $-666,670 and missed earnings estimates by -$.04.
In the last 3 years, COGT traded as high as $43.73 and as low as $3.67.
The top ETF exchange traded funds that COGT belongs to (by Net Assets): VTI, IWM, XBI, VB, VBR.
COGT has outperformed the market in the last year with a price return of +115.0% while the SPY ETF gained +10.8%. However, in the short term, COGT had mixed performance relative to the market. It has underperformed in the last 3 months, returning -24.3% vs -4.1% return in SPY. But in the last 2 weeks, COGT shares have fared better than the market returning +1.4% compared to SPY -3.2%.
COGT support price is $28.61 and resistance is $30.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that COGT shares will trade within this expected range on the day.
